SG11201806855WA - Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine - Google Patents

Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine

Info

Publication number
SG11201806855WA
SG11201806855WA SG11201806855WA SG11201806855WA SG11201806855WA SG 11201806855W A SG11201806855W A SG 11201806855WA SG 11201806855W A SG11201806855W A SG 11201806855WA SG 11201806855W A SG11201806855W A SG 11201806855WA SG 11201806855W A SG11201806855W A SG 11201806855WA
Authority
SG
Singapore
Prior art keywords
medivir
box
international
huddinge
troxacitabine
Prior art date
Application number
SG11201806855WA
Inventor
Mark Albertella
Anders Eneroth
Björn Klasson
Fredrik ÖBERG
John Öhd
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of SG11201806855WA publication Critical patent/SG11201806855WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

XO H (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/151044 Al 8 September 2017 (08.09.2017) WIPO I PCT 111111111111110111011111111111010111110 01111111101011111111111111111111111110111111 W O 20 17 / 15 10 44 Al (51) International Patent Classification: A61K 31/513 (2006.01) A61P 35/00 (2006.01) A61K 31/4412 (2006.01) (21) International Application Number: PCT/SE2017/050186 (22) International Filing Date: 28 February 2017 (28.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1650274-2 2 March 2016 (02.03.2016) SE 1651204-8 8 September 2016 (08.09.2016) SE (71) Applicant: MEDIVIR AB [SE/SE]; Box 1086, 141 22 Huddinge (SE). (72) Inventors: ALBERTELLA, Mark; C/o Medivir Ab, Box 1086, 141 22 Huddinge (SE). ENEROTH, Anders; C/o Medivir AB, Box 1086, 141 22 Huddinge (SE). KLAS- SON, Bjorn; C/o Medivir AB, Box 1086, 141 22 Hud- dinge (SE). ()BERG, Fredrik; C/o Medivir AB, Box 1086, 141 22 Huddinge (SE). OHD, John; C/o Medivir AB, Box 1086, 141 22 Huddinge (SE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: COMBINATION THERAPY WITH SORAFENIB OR REGORAFENIB AND A PHOSPHORAMIDATE PRODRUG = OF TROXACITABINE (57) : Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C I -C straight or branched chain alkyl, X is H, halo, C s 3 -C 4 cycloalkyl or C i -C 4 alkyl and Z is H or fluoro, or a pharmaceut- ically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis.
SG11201806855WA 2016-03-02 2017-02-28 Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine SG11201806855WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1650274 2016-03-02
SE1651204 2016-09-08
PCT/SE2017/050186 WO2017151044A1 (en) 2016-03-02 2017-02-28 Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine

Publications (1)

Publication Number Publication Date
SG11201806855WA true SG11201806855WA (en) 2018-09-27

Family

ID=59744330

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806855WA SG11201806855WA (en) 2016-03-02 2017-02-28 Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine

Country Status (12)

Country Link
US (2) US10456413B2 (en)
EP (1) EP3423061A4 (en)
JP (1) JP6968080B2 (en)
KR (1) KR20180118745A (en)
CN (2) CN109069509B (en)
AU (2) AU2017227516B2 (en)
BR (1) BR112018067387A2 (en)
CA (1) CA3014769C (en)
RU (1) RU2018134336A (en)
SG (1) SG11201806855WA (en)
WO (1) WO2017151044A1 (en)
ZA (1) ZA201805445B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6968080B2 (en) 2016-03-02 2021-11-17 メディヴィル・アクチエボラーグ Combination therapy with sorafenib or regorafenib and troxacitabine phosphoramidate prodrug
WO2019149279A1 (en) * 2018-02-02 2019-08-08 科济生物医药（上海）有限公司 Combination of cellular immunotherapy
KR20210130768A (en) * 2019-02-18 2021-11-01 메디비르 아베 Method for treating liver cancer using orally administered dioxolane nucleotides in combination with anti-PD1 or anti-PDL1 monoclonal antibody
JP2023522325A (en) * 2020-04-15 2023-05-30 メディヴィル・アクチエボラーグ MIV-818/lenvatinib combination therapy for liver cancer
KR20210156389A (en) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 Pharmaceutical composition for the prevention or treatment of inflammatory disease comprising regorafenib an active ingredient
IT202000022636A1 (en) 2020-09-25 2022-03-25 Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter “COMBINATION THERAPY OF SORAFENIB AND/OR REGORAFENIB WITH THE RECOMBINANT HUMAN PROTEOGLYCAN-4 PROTEIN FOR THE TREATMENT OF HEPATOCARCINOMA”

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US20030013660A1 (en) * 2000-10-13 2003-01-16 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2526617C (en) 2003-05-20 2015-04-28 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
UA84156C2 (en) * 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CN101415409B (en) * 2006-04-05 2012-12-05 诺瓦提斯公司 Combinations of therapeutic agents for treating cancer
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
CN102190616B (en) 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 A kind of deuterated synthesis of ω-diphenyl urea and the Method and process of production
KR20230004871A (en) 2012-04-13 2023-01-06 에피자임, 인코포레이티드 Combination therapy for treating cancer
CN103570613B (en) 2012-07-18 2016-06-15 苏州泽璟生物制药有限公司 The polymorphic form of deuterated ω-diphenyl urea or its salt
AU2013296897B2 (en) 2012-07-28 2015-09-17 Beijing Findcure Biosciences Ltd. Substituted pyrazolone compounds and methods of use
US9872919B2 (en) * 2012-09-19 2018-01-23 The Research Foundation For The State University Of New York Prodrugs for selective anticancer therapy
KR20160099090A (en) * 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 Nucleotides for the treatment of liver cancer
EP3074399A1 (en) * 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
PT3186244T (en) * 2014-08-25 2020-05-29 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer
JP6968080B2 (en) 2016-03-02 2021-11-17 メディヴィル・アクチエボラーグ Combination therapy with sorafenib or regorafenib and troxacitabine phosphoramidate prodrug

Also Published As

Publication number Publication date
CN111956646A (en) 2020-11-20
EP3423061A4 (en) 2019-11-13
BR112018067387A2 (en) 2019-01-02
US10456413B2 (en) 2019-10-29
CA3014769C (en) 2024-01-09
US20200009166A1 (en) 2020-01-09
CN111956646B (en) 2023-07-25
CA3014769A1 (en) 2017-09-08
US10960017B2 (en) 2021-03-30
EP3423061A1 (en) 2019-01-09
AU2017227516A1 (en) 2018-08-30
WO2017151044A1 (en) 2017-09-08
US20190091246A1 (en) 2019-03-28
JP6968080B2 (en) 2021-11-17
KR20180118745A (en) 2018-10-31
CN109069509A (en) 2018-12-21
ZA201805445B (en) 2019-07-31
CN109069509B (en) 2020-10-16
RU2018134336A (en) 2020-04-02
AU2017227516B2 (en) 2022-03-03
AU2022203761A1 (en) 2022-06-16
RU2018134336A3 (en) 2020-05-22
JP2019507764A (en) 2019-03-22

Similar Documents

Publication Publication Date Title
SG11201806855WA (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201804934PA (en) Novel Compounds
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201408094YA (en) Neprilysin inhibitors
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201808108XA (en) Synthesis of indazoles
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201804888WA (en) Velocity model update with an inversion gradient
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201901251SA (en) Aminopyrimidines as alk inhibitors
SG11201804885TA (en) Monomaleimide-functionalized platinum compounds for cancer therapy
SG11201808686VA (en) Synthesis of indazoles
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201810268YA (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors